BioSpace News Archive

Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), a pharmaceutical company focused on the discovery, development and commercialization of first-in-class ophthalmic therapies, today announced that it will present first quarter 2022 financial results after the market closes Thursday, May 5, 2022.

Alpha Cognition Inc. reported financial results for the fourth quarter and full year ended December 31, 2021.

Veracyte, Inc. announced that three abstracts highlighting new data on the genomic underpinnings of prostate and bladder cancers will be presented at the American Urological Association Annual Meeting, taking place May 13-16, 2022, in New Orleans.

Sunshine Biopharma, Inc. closed its previously announced private placement pursuant to a securities purchase agreement entered into on April 25, 2022 with certain institutional and accredited investors for aggregate gross proceeds of approximately $19.5 million, before deducting fees to the placement agent and other offering expenses payable by the Company.

Thermo Fisher Scientific Inc., the world leader in serving science, reported its financial results for the first quarter ended April 2, 2022.

Centogene N.V. announced it has extended its partnership with Takeda to diagnose patients with rare metabolic and rare neurodegenerative diseases.

Alzamend Neuro, Inc. announced that Digital Power Lending, LLC, a wholly owned subsidiary of BitNile Holdings, Inc., a diversified holding company, has made an additional investment in the Company.

Merck, known as MSD outside the United States and Canada, announced financial results for the first quarter of 2022.

Lytix Biopharma AS (Lytix), a clinical-stage company with an in situ vaccination technology platform targeting cancer indications, today announces that its abstract has been accepted for poster presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago June 3-7, 2022.

Labcorp (NYSE: LH), a leading global life sciences company, today announced results for the first quarter ended March 31, 2022, and updated full-year guidance.